Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
30 hedge funds and large institutions have $21.2M invested in Allena Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 6 closing their positions.
52% more capital invested
Capital invested by funds: $14M → $21.2M (+$7.2M)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
3% more funds holding
Funds holding: 29 → 30 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.57M |
| 2 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
+$666K |
| 3 |
Renaissance Technologies
New York
|
+$362K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$256K |
| 5 |
Squarepoint
New York
|
+$86.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DVC
Deer VII & Co
Larchmont,
New York
|
-$2.17M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$643K |
| 3 |
Millennium Management
New York
|
-$358K |
| 4 |
Morgan Stanley
New York
|
-$291K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$84.2K |
ALNA Hedge Fund Activity: Q2 2020 in Review
30 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q2 2020, worth a combined $21.2M — up 52% from $14M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ALNA positions and 6 closed out — a net gain of 1 holder — while 7 added to existing stakes and 9 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.57M. The largest seller was Deer VII & Co, exiting entirely with an estimated $2.17M sold.
- 30 institutional investors held Allena Pharmaceuticals (ALNA) as of Q2 2020, up from 29 in Q1 2020.
- Funds reported $21.2M of Allena Pharmaceuticals stock for Q2 2020, up 52% quarter-over-quarter.
- 7 funds opened new Allena Pharmaceuticals positions in Q2 2020 and 6 closed out, a net change of +1 holder.
- The largest Allena Pharmaceuticals buyer in Q2 2020 was Sabby Management, an estimated $2.57M added.
- The largest Allena Pharmaceuticals seller in Q2 2020 was Deer VII & Co, an estimated $2.17M sold.
Based on aggregated 13F filings for Q2 2020.